Clinical Trials - Phase II
Filter News
Found 29,772 articles
-
Isis Pharmaceuticals, Inc. Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients With Familial Chylomicronemia
9/23/2013
-
Alexion Pharmaceuticals Inc. Release: New Data Evaluating Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP) Presented at Paediatric Endocrinology Meeting
9/23/2013
-
Isis Pharmaceuticals, Inc. to Conduct Webcast and Conference Call to Discuss ISIS-APOCIII Rx Phase 2 Data
9/23/2013
-
Boehringer Ingelheim Corporation's Volasertib Wins FDA Breakthrough Therapy Designation
9/20/2013
-
Cyclacel Pharmaceuticals, Inc.'s Sapacitabine Reported to Have Anti-Tumor Activity Against Ovarian Cancer
9/20/2013
-
Prima Biomed's Ovarian Cancer Treatment Shows No Difference in Phase 2 Study
9/19/2013
-
Mesoblast Limited's Phase 2 Trial For Lumbar Spinal Fusion Selected For Presentation at Premier Spine Conference
9/19/2013
-
Omeros Corporation Reports Initiation of Phase 2 Clinical Trial With OMS824
9/19/2013
-
Viralytics Ltd Meets Primary Endpoint in CAVATAK Phase 2 Melanoma Trial
9/18/2013
-
Creabilis SA Announces Treatment of First Patients in its Phase 2b Trial of CT327 in Pruritus in Atopic Dermatitis Patients
9/18/2013
-
Elcelyx Therapeutics to Present Clinical Data on NewMet in Type 2 Diabetes at the 49th Annual European Association for the Study of Diabetes Meeting
9/17/2013
-
Agenus (Formerly known as Antigenics Inc. - Lexington, MA) Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine in Newly Diagnosed Patients
9/17/2013
-
NeoStem, Inc. Reports Third Data Safety Monitoring Board Review of PreSERVE AMI Trial
9/17/2013
-
Aptiv Solutions Launches ADDPLAN® DF for Optimizing Dose Selection in Phase 2 Trials
9/17/2013
-
FDA Lifts Clinical Hold of Pluristem Therapeutics's Phase 2 Intermittent Claudication Study
9/16/2013
-
NovaBay Pharmaceuticals, Inc.'s Auriclosene Cuts Down Blockages in Catheters in Phase 2 Trial
9/16/2013
-
Aastrom Biosciences, Inc. Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada
9/16/2013
-
JAIDS Study by Argos Therapeutics, Inc. Evaluates Impact of Personalized Immunotherapy in HIV-Infected Patients
9/16/2013
-
Ultragenyx Pharmaceuticals Announces Positive Data From Retrospective Study of UX007 Triheptanoin in Patients With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
9/16/2013
-
Versartis, Inc. Receives Orphan Drug Status for Its Novel Long-Acting Growth Hormone Treatment From European Commission (EC)
9/13/2013